Josh Brown stated on CNBC that he wants to focus on stocks unrelated to data centers and GPUs. He is bullish on Incyte (Nasdaq: INCY) and Biogen (Nasdaq: BIIB). Incyte has risen 22% year-to-date, with Q2 revenue up 38% year-over-year and net product sales up 40%, both exceeding Wall Street expectations. The company also raised its full-year FY2026 sales guidance by approximately 7% and expects about 10 clinical data readouts in the second half of the year.